Adavosertib

Generic Name
Adavosertib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C27H32N8O2
CAS Number
955365-80-7
Unique Ingredient Identifier
K2T6HJX3I3
Background

MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

First Posted Date
2015-11-20
Last Posted Date
2023-07-03
Lead Sponsor
AstraZeneca
Target Recruit Count
62
Registration Number
NCT02610075
Locations
🇺🇸

Research Site, Nashville, Tennessee, United States

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Phase 2
Completed
Conditions
Small Cell Lung Cancer
Interventions
Drug: AZD1775
First Posted Date
2015-10-30
Last Posted Date
2021-03-19
Lead Sponsor
Samsung Medical Center
Target Recruit Count
24
Registration Number
NCT02593019
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

First Posted Date
2015-10-26
Last Posted Date
2021-06-29
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
12
Registration Number
NCT02585973
Locations
🇺🇸

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

OLAParib COmbinations

Phase 2
Terminated
Conditions
Cancer
Interventions
Drug: AZD2281
Drug: AZD5363
Drug: AZD6738
Drug: AZD1775
First Posted Date
2015-10-15
Last Posted Date
2022-12-28
Lead Sponsor
Joseph Paul Eder
Target Recruit Count
67
Registration Number
NCT02576444
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

First Posted Date
2015-09-11
Last Posted Date
2024-12-12
Lead Sponsor
AstraZeneca
Target Recruit Count
117
Registration Number
NCT02546661
Locations
🇬🇧

Research Site, Southampton, United Kingdom

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Interventions
Drug: Carboplatin
Drug: Paclitaxel
Drug: AZD1775
First Posted Date
2015-07-31
Last Posted Date
2024-05-10
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
42
Registration Number
NCT02513563
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

First Posted Date
2015-07-30
Last Posted Date
2019-11-07
Lead Sponsor
AstraZeneca
Target Recruit Count
128
Registration Number
NCT02511795
Locations
🇨🇦

Research Site, Toronto, Ontario, Canada

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

First Posted Date
2015-06-26
Last Posted Date
2023-07-03
Lead Sponsor
AstraZeneca
Target Recruit Count
92
Registration Number
NCT02482311
Locations
🇨🇦

Research Site, Toronto, Ontario, Canada

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2
Active, not recruiting
Conditions
Advanced Malignant Solid Neoplasm
Breast Carcinoma
Cervical Carcinoma
Liver Carcinoma
Malignant Uterine Neoplasm
Recurrent Gastric Carcinoma
Recurrent Head and Neck Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Prostate Carcinoma
Recurrent Rectal Carcinoma
Interventions
Drug: Afatinib
Drug: Capivasertib
Drug: Binimetinib
Drug: Adavosertib
Procedure: Biospecimen Collection
Other: Cytology Specimen Collection Procedure
Drug: Afatinib Dimaleate
Drug: Dabrafenib
Drug: Defactinib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Procedure: Biopsy
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: Taselisib
Drug: Sapanisertib
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Drug: Palbociclib
Biological: Nivolumab
Drug: Copanlisib
Drug: Ulixertinib
Biological: Trastuzumab Emtansine
Drug: Copanlisib Hydrochloride
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Procedure: Echocardiography
Drug: Osimertinib
Biological: Trastuzumab
Drug: Larotrectinib Sulfate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging
First Posted Date
2015-06-08
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
6452
Registration Number
NCT02465060
Locations
🇺🇸

Alaska Women's Cancer Care, Anchorage, Alaska, United States

🇺🇸

Anchorage Oncology Centre, Anchorage, Alaska, United States

🇺🇸

Katmai Oncology Group, Anchorage, Alaska, United States

and more 1416 locations

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

First Posted Date
2015-05-19
Last Posted Date
2022-06-15
Lead Sponsor
Samsung Medical Center
Target Recruit Count
26
Registration Number
NCT02448329
Locations
🇰🇷

Samsung Medical center, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy